New findings reveal sotagliflozin's benefits for patients with heart failure with preserved ejection fraction without ...

Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing next-generation therapeutics, today announced that positive interim data ...

Among patients with heart failure and reduced ejection fraction (HFrEF), those taking a “polypill” combination of three medications typically prescribed for heart failure, once daily for six months, ...

According to the American College of Cardiology, nearly 6.7 million Americans have heart failure, more than half with preserved ejection fraction. This condition often leads to frequent ...

Among patients with heart failure and reduced ejection fraction (HFrEF), those taking a "polypill" combination of three ...

Adults with heart failure with reduced ejection fraction (HFrEF) who took a "polypill" combining medications prescribed for the treatment of heart failure, had improved heart function and symptoms, ...

Tempus AI shows strong Q3 growth with 85% higher sales, robust oncology and data licensing momentum, and attractive 7.5x ’26 ...

Inspired by hibernating squirrels, scientists have developed a promising new drug that could transform how we treat heart ...

Wave's pivotal trial, Dr. William Abraham is working on another heart failure trial as the new CMO at Cardiac Dimensions.

Winrevair yielded significant and meaningful clinical benefits for patients with combined post- and precapillary pulmonary ...

Despite making up half of the 64 million people living with heart failure, patients with this common form have no access to ...